Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vestergaard

Showing results (111-120 of 520) with videos related to

Pageof 52
Sort By:
Canadian Journal of Diabetes|February 8, 2026
Future Directions for Diabetic Foot Ulcer Interventions: A Scoping Review of Continuous Glucose Monitoring based TelemedicineClara Bender, Peter Vestergaard, Simon Lebech Cichosz
Bone|March 25, 2023
Discrepancies in type of first major osteoporotic fracture and anti-osteoporotic therapy in elderly people with type 2 diabetes mellitus: A retrospective Danish cohort studyRikke Viggers, Jakob Starup-Linde, Peter Vestergaard
The Journal of Clinical Endocrinology and Metabolism|January 18, 2014
WITHDRAWN: Low-density lipoprotein cholesterol is associated with fracture risk in diabetes patients - a nested case-control studyJakob Starup-Linde, Soeren Gregersen, Peter Vestergaard
Bone|December 25, 2018
Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture preventionBo Abrahamsen, Michael K Skjødt, Peter Vestergaard
Diabetes/Metabolism Research and Reviews|October 25, 2019
Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort studyMorten Hasselstrøm Jensen, Ole Hejlesen, Peter Vestergaard
Ugeskrift for Laeger|September 7, 2004
[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis]Peter Vestergaard, Lars Rejnmark Nielsen, Leif Mosekilde
Ugeskrift for Laeger|September 15, 2005
[Overweight, obesity and risk factors for atrial fibrillation or flutter--secondary publication. The cohort study Diet, Cancer and Health]Lars Frost, Lone Juul Hune, Peter Vestergaard
Ugeskrift for Laeger|August 7, 2014
[Hormone replacement therapy as primary prevention?]Pia Eiken, Peter Vestergaard, Jens-Erik Jensen
Ugeskrift for Laeger|January 6, 2006
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism]Peter Vestergaard, Lars Rejnmark Nielsen, Leif Mosekilde
Archives of Osteoporosis|October 3, 2015
Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort studyAnne-Luise Thorsteinsson, Peter Vestergaard, Pia Eiken
Pageof 52

Showing results (111-120 of 520) with videos related to

Sort By:
Pageof 52
Canadian Journal of Diabetes|February 8, 2026
Future Directions for Diabetic Foot Ulcer Interventions: A Scoping Review of Continuous Glucose Monitoring based TelemedicineClara Bender, Peter Vestergaard, Simon Lebech Cichosz
Bone|March 25, 2023
Discrepancies in type of first major osteoporotic fracture and anti-osteoporotic therapy in elderly people with type 2 diabetes mellitus: A retrospective Danish cohort studyRikke Viggers, Jakob Starup-Linde, Peter Vestergaard
The Journal of Clinical Endocrinology and Metabolism|January 18, 2014
WITHDRAWN: Low-density lipoprotein cholesterol is associated with fracture risk in diabetes patients - a nested case-control studyJakob Starup-Linde, Soeren Gregersen, Peter Vestergaard
Bone|December 25, 2018
Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture preventionBo Abrahamsen, Michael K Skjødt, Peter Vestergaard
Diabetes/Metabolism Research and Reviews|October 25, 2019
Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort studyMorten Hasselstrøm Jensen, Ole Hejlesen, Peter Vestergaard
Ugeskrift for Laeger|September 7, 2004
[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis]Peter Vestergaard, Lars Rejnmark Nielsen, Leif Mosekilde
Ugeskrift for Laeger|September 15, 2005
[Overweight, obesity and risk factors for atrial fibrillation or flutter--secondary publication. The cohort study Diet, Cancer and Health]Lars Frost, Lone Juul Hune, Peter Vestergaard
Ugeskrift for Laeger|August 7, 2014
[Hormone replacement therapy as primary prevention?]Pia Eiken, Peter Vestergaard, Jens-Erik Jensen
Ugeskrift for Laeger|January 6, 2006
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism]Peter Vestergaard, Lars Rejnmark Nielsen, Leif Mosekilde
Archives of Osteoporosis|October 3, 2015
Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort studyAnne-Luise Thorsteinsson, Peter Vestergaard, Pia Eiken
Pageof 52